|
1
|
Ettinger DS, Wood DE, Aggarwal C, Aisner
DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac
LR, et al: NCCN guidelines insights: Non-small cell lung cancer,
version 1.2020. J Natl Compr Canc Netw. 17:1464–1472.
2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Dalakas MC: Neurological complications of
immune checkpoint inhibitors: What happens when you ‘take the
brakes off’ the immune system. Ther Adv Neurol Disord.
11(1756286418799864)2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Brahmer JR, Lacchetti C, Schneider BJ,
Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner
JM, Ginex P, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: American
society of clinical oncology clinical practice guideline. J Clin
Oncol. 36:1714–1768. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment
of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gandhi L, Rodriguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et
al: Durvalumab after chemoradiotherapy in stage III non-small-cell
lung cancer. N Engl J Med. 377:1919–1929. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ready N, Farago AF, de Braud F, Atmaca A,
Hellmann MD, Schneider JG, Spigel DR, Moreno V, Chau I, Hann CL, et
al: Third-line nivolumab monotherapy in recurrent SCLC: CheckMate
032. J Thorac Oncol. 14:237–244. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Horn L, Mansfield AS, Szczesna A, Havel L,
Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio
M, et al: First-line atezolizumab plus chemotherapy in
extensive-stage small-cell lung cancer. N Engl J Med.
379:2220–2229. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Waghdhare S, Kalantri A, Joshi R and
Kalantri S: Accuracy of physical signs for detecting meningitis: A
hospital-based diagnostic accuracy study. Clin Neurol Neurosurg.
112:752–757. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Blackmon JT, Viator TM and Conry RM:
Central nervous system toxicities of anti-cancer immune checkpoint
blockade. J Neurol Neuromedicine. 1:39–45. 2016.
|
|
12
|
Fujiwara S, Mimura N, Yoshimura H,
Fujimoto D, Ito M, Mori R, Ito J, Tomii K, Kawamoto M and Kohara N:
Elevated adenosine deaminase levels in the cerebrospinal fluid in
immune checkpoint inhibitor-induced autoimmune encephalitis. Intern
Med. 58:2871–2874. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tuon FF, Higashino HR, Lopes MI, Litvoc
MN, Atomiya AN, Antonangelo L and Leite OM: Adenosine deaminase and
tuberculous meningitis-a systematic review with meta-analysis.
Scand J Infect Dis. 42:198–207. 2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yonenobu Y, Ishijima M, Toyooka K and
Fujimura H: A case of meningoencephalitis associated with
pembrolizumab treated for squamous cell lung cancer. Rinsho
Shinkeigaku. 59:105–108. 2019.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
15
|
Thwaites GE and Hien TT: Tuberculous
meningitis: Many questions, too few answers. Lancet Neurol.
4:160–170. 2005.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Akaishi T, Narikawa K, Suzuki Y, Mitsuzawa
S, Tsukita K, Kuroda H, Nakashima I, Fujihara K and Aoki M:
Importance of the quotient of albumin, quotient of immunoglobulin G
and Reibergram in inflammatory neurological disorders with
disease-specific patterns of blood-brain barrier permeability.
Neurol Clin Neurosci. 3:94–100. 2015.
|
|
17
|
Leitinger M, Varosanec MV, Pikija S, Wass
RE, Bandke D, Weis S, Studnicka M, Grinzinger S, McCoy MR, Hauer L
and Sellner J: Fatal necrotizing encephalopathy after treatment
with nivolumab for squamous non-small cell lung cancer: Case report
and review of the literature. Front Immunol. 9(108)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Glantz MJ, Cole BF, Glantz LK, Cobb J,
Mills P, Lekos A, Walters BC and Recht LD: Cerebrospinal fluid
cytology in patients with cancer: Minimizing false-negative
results. Cancer. 82:733–739. 1998.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Spain L, Walls G, Julve M, O'Meara K,
Schmid T, Kalaitzaki E, Turajlic S, Gore M, Rees J and Larkin J:
Neurotoxicity from immune-checkpoint inhibition in the treatment of
melanoma: A single centre experience and review of the literature.
Ann Oncol. 28:377–385. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Bot I, Blank CU, Boogerd W and Brandsma D:
Neurological immune-related adverse events of ipilimumab. Pract
Neurol. 13:278–280. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Voskens CJ, Goldinger SM, Loquai C, Robert
C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T,
Fluck M, et al: The price of tumor control: An analysis of rare
side effects of anti-CTLA-4 therapy in metastatic melanoma from the
ipilimumab network. PLoS One. 8(e53745)2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bompaire F, Mateus C, Taillia H, De
Greslan T, Lahutte M, Sallansonnet-Froment M, Ouologuem M, Renard
JL, Gorochov G, Robert C and Ricard D: Severe
meningo-radiculo-neuritis associated with ipilimumab. Invest New
Drugs. 30:2407–2410. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yang JC, Hughes M, Kammula U, Royal R,
Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, et
al: Ipilimumab (anti-CTLA4 antibody) causes regression of
metastatic renal cell cancer associated with enteritis and
hypophysitis. J Immunother. 30:825–830. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Takamatsu D, Furubayashi N, Negishi T,
Ieiri K, Inoue T, Tsukino K and Nakamura M: Relapse of aseptic
meningitis induced by ipilimumab and nivolumab therapy for
metastatic renal cell carcinoma: A case report. Mol Clin Oncol.
11:590–594. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cordes LM, Davarpanah NN, Reoma LB, Gasmi
B, Quezado M, Khan OI, Nath A and Apolo AB: Neurotoxicities
associated with checkpoint inhibitors: Two case reports and a
review of the literature. Clin Case Rep. 8:24–32. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Toyozawa R, Haratake N, Toyokawa G,
Matsubara T, Takamori S, Miura N, Yamaguchi M, Takenoyama M and
Seto T: Atezolizumab-induced aseptic meningitis in patients with
NSCLC. JTO Clin Res Rep. 1(100012)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lima G, Kahn A, Sama S and Savage J:
Aseptic meningitis as an immune-related adverse event after
pembrolizumab. Case Rep Oncol Med. 2019(7183747)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tadano H and Torigoe T: Immune-related
adverse events of immune checkpoint inhibitors. Nihon Rinsho Meneki
Gakkai Kaishi. 40:102–108. 2017.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
29
|
Horvat TZ, Adel NG, Dang TO, Momtaz P,
Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo
KM, et al: Immune-related adverse events, need for systemic
immunosuppression, and effects on survival and time to treatment
failure in patients with melanoma treated with ipilimumab at
memorial sloan kettering cancer center. J Clin Oncol. 33:3193–3198.
2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Polman CH, O'Connor PW, Havrdova E,
Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD,
Giovannoni G, Wajgt A, et al: A randomized, placebo-controlled
trial of natalizumab for relapsing multiple sclerosis. N Engl J
Med. 354:899–910. 2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hottinger AF, de Micheli R, Guido V,
Karampera A, Hagmann P and Du Pasquier R: Natalizumab may control
immune checkpoint inhibitor-induced limbic encephalitis. Neurol
Neuroimmunol Neuroinflamm. 5(e439)2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Teraoka S, Fujimoto D, Morimoto T, Kawachi
H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, et al:
Early immune-related adverse events and association with outcome in
advanced non-small cell lung cancer patients treated with
nivolumab: A prospective cohort study. J Thorac Oncol.
12:1798–1805. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Niki M, Nakaya A, Kurata T, Nakahama K,
Yoshioka H, Kaneda T, Kibata K, Ogata M and Nomura S:
Pembrolizumab-induced autoimmune encephalitis in a patient with
advanced non-small cell lung cancer: A case report. Mol Clin Oncol.
10:267–269. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Simonaggio A, Michot JM, Voisin AL, Le
Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A,
Varga A, et al: Evaluation of readministration of immune checkpoint
inhibitors after immune-related adverse events in patients with
cancer. JAMA Oncol. 5:1310–1317. 2019.PubMed/NCBI View Article : Google Scholar
|
